Physician profile
David S Geller
NPI 1093786402
$1,327.13
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $247 · 2021: $391 · 2022: $249 · 2023: $71.55 · 2024: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $227.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $210.96 | 2020-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $182.40 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $168.81 | 2019-2021 | |
| Seqirus USA INC | $105.24 | 2021-2024 | Flucelvax, Flucelvax Quadrivalent |
| Ironshore Pharmaceuticals INC. | $99.74 | 2019-2024 | |
| Pfizer INC. | $97.39 | 2019-2021 | |
| Neos Therapeutics, LP | $94.45 | 2019-2022 | |
| Glaxosmithkline, LLC. | $93.34 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $78.29 | 2022-2024 | Flumist Quadrivalent |
| Supernus Pharmaceuticals, INC. | $36.17 | 2022 | |
| Tris Pharma INC | $32.34 | 2021 | |
| Cranial Technologies, INC | $31.71 | 2024 | Doc Band |
| Alexion Pharmaceuticals, INC. | $22.40 | 2020 | |
| Phadia US INC. | $22.17 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $21.42 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $16.22 | 2023 | Valtoco |
| Hologic Sales and Service, LLC | $14.08 | 2023 | Aptima, Third Wave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Geller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.